ClinicalTrials.gg
RecruitingNCT07423000Updated Sep 30, 2026

A Phase 1 Study of PVT401 in Healthy Subjects

A Phase 1 interventional study of PVT401 and Normal Saline (0.9% NaCl) in Inflammatory Bowel Disease (IBD), sponsored by Parvus Therapeutics, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Parvus Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Inflammatory Bowel Diseases with a site in Australia — 12 open to participants now, 14 under way, 3 of them phase 3. Inflammatory Bowel Diseases · Australia.

Planned enrollment
43rd of 50
36 · median 134
Started
2026
with 4 others
Phase 1
8 of 55
3 open now
Primary completion
2027-11
later than 9 of 13 live
Registered
51st of 55
by date

Among the 55 studies in Inflammatory Bowel Diseases with a site in Australia, this one is the 43rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 9 of the 13 other live ones, and was the 51st registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

12 of the 55 studies in Inflammatory Bowel Diseases with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Inflammatory Bowel Diseases with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn what happens to PVT401 when it enters the human body and how it affects the immune system. It will also provide information about the safety of PVT401 after a single dose and after multiple doses. The main questions it aims to answer are:

Will participants experience any side effects when taking PVT401? How long does it take PVT401 to leave the body after it is administered?

Healthy volunteers will participate in either the single ascending dose (SAD) or multiple ascending dose (MAD) phase.

In the SAD phase, participants will:

stay in the clinic for two nights, get one dose of PVT401 or a placebo intravenously (through a vein) on Day 1, have blood drawn periodically throughout their stay and be monitored for side effects, and return to the clinic for 3 follow up visits over the four weeks after dosing.

In the MAD phase, participants will:

stay in the clinic for one night prior to each dose of PVT401 or placebo, and get dosed twice a week for 5 weeks. They will have blood drawn periodically throughout the treatment period and be monitored for side effects, and return to the clinic for 4 follow up visits over the six months after dosing.

Read the detailed description

SAD Phase: four cohorts are planned (n=6 per cohort; 2:1 randomization of PVT401 to placebo). This phase consists of five study visits: Screening, Treatment, and Follow-up (Day 8, Day 15, and Day 29). The Screening and Follow-up visits are outpatient; the Treatment visit includes a two-night inpatient stay from Day -1 to Day 2.

Participants will be admitted to the clinic on Day -1, the day prior to dosing. PK sampling will take place on Day 1, and the safety and tolerability of the study drug will be monitored for each participant in the clinic until Day 2 (24 hours post-dose) checkout.

The decision to advance to the subsequent SAD dose cohort will be made by a Safety Review Committee (SRC) following review of all available safety and tolerability data of participants through Day 8.

After completion of a minimum of four cohorts and with the approval of the SRC, the study will transition to the MAD phase.

MAD Phase: two cohorts are planned (n=6 per cohort; 2:1 randomization of PVT401 to placebo). This phase consists of 15 study visits: Screening: Visit 1, Treatment (Visits 2 - 11, dosing b.i.w. for 5 weeks), and Follow-up (Visits 12 - 15, up to 6 months post-dose).

All Treatment visits include a one-night inpatient stay prior to dosing; the Screening and Follow-up visits are outpatient.

The Screening visit can take place up to 42 days prior to Day 1. Participants will check in to the clinic on Day -1, the day prior to the first planned dose on Day 1. Dosing in each cohort will commence with two sentinel participants randomized such that one will receive PVT401 and the other will receive placebo (normal saline; 0.9% sodium chloride). The safety and tolerability of the study drug will be monitored for each sentinel participant through the first two doses (Week 1, Day 1 and Day 4) and will be reviewed by the Investigator prior to dosing the remainder of the participants in the cohort. Following completion of the Day 4 assessments for sentinel participants, all available safety/tolerability information will be reviewed by the Investigator prior to making the decision to dose the remaining participants in each cohort. Once safety and tolerability have been confirmed, the remaining four participants will be randomised (3:1 ratio of PVT401:placebo).

On Week 1, Day 1, all participants will remain for 8 hours after their first dose for observation and PK sampling prior to discharge. Participants will also remain for assessments and observation for a minimum of 8 hours post-dose at all other dosing visits.

The decision to advance to the next MAD dose cohort will be made by the SRC after completion of the five-week dosing cycle, following review of all available safety and tolerability data from the previous cohorts.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)

Keywords

  • Phase 1
  • First-in-human
  • Single ascending dose
  • Multiple ascending dose
  • Healthy volunteers
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female, aged between 18 and 65 years, inclusive at Screening.
  2. (BMI) of 18.0 to 32.0 kg/m2, inclusive.
  3. Carry the HLA DRB4*0101 or DRB4*0103 allele.
  4. Participant is medically healthy (in the opinion of the Investigator), as determined by pre-study medical history and without (CS) abnormalities.
  5. Female participants must be of non-, or, if of child-bearing potential, must have negative pregnancy test, agree not to become pregnant or donate ova, and must agree to use adequate .
  6. Male participants must agree not to donate sperm and use adequate contraception.

Exclusion criteria

Exclusion Criteria:

  1. Any active infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.
  2. History of reaction, anaphylaxis or other CS reactions or known allergy to the study drug or its ingredients including but not limited to dextran.
  3. History of any CS disorder which, in the opinion of the Investigator would make implementation of the protocol or interpretation of study results difficult, or that would put the participant at risk by participating in the study.
  4. History of surgery or hospitalisation within 4 weeks prior to Screening, or surgery planned during the study.
  5. Participant has donated blood or blood products or experienced significant blood loss within 2 months prior to the first dose of study drug.
  6. Use of any vaccinations within 4 weeks prior to the first dose of study drug.
  7. Laboratory results at Screening that indicate inadequate renal function, with estimated of \< 60 mL/min/1.73m2.
  8. Use of any prescription medication within 14 days prior to the first dose of study drug and/or over-the-counter medication/vitamins/supplements/herbal/ plant-derived medications within 7 days prior to the first dose of study drug.
  9. Concurrent enrolment in another clinical study, or participation in another clinical study within 30 days or 5 half-lives, whichever is longer, prior to Screening.
  10. Regular consumption of > 10 standard alcoholic drinks/week. Participant is unwilling to abstain from alcohol while confined to the study clinic.
  11. Positive alcohol breath test at Screening, upon admission to the clinic on Day -1.
  12. Positive urine drugs of abuse test at Screening, upon admission to the clinic on Day -1.
  13. Participant is a heavy smoker, define as more than 2 cigarettes per day or 10 per week.
  14. Participant is unwilling to abstain from smoking while confined to the study clinic.
  15. Participant is breastfeeding/lactating or pregnant, or planning to breastfeed or become pregnant during the study.
  16. Positive surface antigen (HBsAg), (HepC) virus antibody, or human immunodeficiency () antibody tests.
  17. Positive for tuberculosis (TB) disease or latent TB infection.
  18. Ingestion of poppy seed-containing foods or beverages within 48 hours prior to first dose of study drug.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    single dose PVT401

    PVT401 will be administered as a single intravenous dose to healthy volunteers. There are a minimum of four cohorts planned, with the dose escalating in each subsequent cohort.

    Drug: PVT401

  • Placebo comparator
    single dose, normal saline

    Participants receiving placebo will be administered a single intravenous dose of normal saline at an equivalent volume to a single IV PVT401 dose (mg/kg).

    Drug: Normal Saline (0.9% NaCl)

  • Experimental
    multiple doses, PVT401

    Following completion of single-dose cohorts, PVT401 will be administered as a multiple intravenous dose treatment regimen to healthy volunteers. There are two cohorts planned, with the dose escalating in each subsequent cohort.

    Drug: PVT401

  • Placebo comparator
    multiple doses, normal saline

    Participants receiving placebo will be administered multiple intravenous doses of normal saline at an equivalent volume to the IV PVT401 dose (mg/kg).

    Drug: Normal Saline (0.9% NaCl)

Interventions

  • DrugPVT401

    Parvus pMHC nanomedicines are being developed for the treatment of autoimmune diseases. They consist of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be recognized by the T-cell antigen receptor. PVT401 is a nanomedicine that will be used to target effector T-cells in patients with inflammatory bowel disease (IBD), converting them to Type 1 regulatory cells. IV delivery in nonclinical models of IBD induced immune tolerance and attenuation of disease pathology without impairing normal immunity to vaccines or viral and bacterial infections. PVT401 will be administered intravenously to healthy volunteers, first as a single dose and then as a multiple dose treatment regimen.

    Also known as: Parvus pMHC nanomedicine

  • DrugNormal Saline (0.9% NaCl)

    All cohorts will be administered either PVT401 or placebo in a ratio of 2:1 PVT401:placebo. Participants receiving placebo will be administered an equivalent volume of normal saline as either a single IV dose or as a multiple dose treatment regimen.

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: adverse and serious adverse events

    Safety endpoints include incidence, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs) (including withdrawals due to AEs)

    Time frame: From enrollment through 4-weeks post last dose of study drug

  2. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: vital signs (temperature)

    Safety endpoints include change from baseline in vital signs (temperature measured in degrees Celsius)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  3. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: vital signs (heart rate)

    Safety endpoints include change from baseline in vital signs (heart rate measured in beats per minute)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  4. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: vital signs (blood pressure)

    Safety endpoints include change from baseline in vital signs (blood pressure measured in mmHg)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  5. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: clinical laboratory parameters (hematology panel)

    Safety endpoints include change from baseline in clinical laboratory parameters (hematology)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  6. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants.: clinical laboratory parameters (serum chemistry panel)

    Safety endpoints include change from baseline in clinical laboratory parameters (serum chemistry including liver function tests).

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  7. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: clinical laboratory parameters (coagulation panel)

    Safety endpoints include change from baseline in clinical laboratory parameters (coagulation parameters).

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  8. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: clinical laboratory parameters (urinalysis)

    Safety endpoints include change from baseline in clinical laboratory parameters (urinalysis).

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  9. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: clinical laboratory parameters (serum iron panel)

    Safety endpoints include change from baseline in clinical laboratory parameters (serum iron panel)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  10. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: ECG (PR interval)

    Safety endpoints include change from baseline in electrocardiogram (ECG) parameters: PR Interval (milliseconds)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  11. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: ECG (QRS duration)

    Safety endpoints include change from baseline in electrocardiogram (ECG) parameters: QRS Duration (milliseconds)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  12. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: ECG (QT interval)

    Safety endpoints include change from baseline in electrocardiogram (ECG) parameters: QT Interval (milliseconds)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

  13. To evaluate the safety and tolerability of a single and multiple IV doses of PVT401 in healthy participants: ECG (QTcF)

    Safety endpoints include change from baseline in electrocardiogram (ECG) parameters: QTcF (milliseconds)

    Time frame: From enrollment through 4 weeks after dosing (single dose cohorts) or 6 months after the final dose (multiple dose cohorts)

Secondary outcomes

  1. To measure the PK of PVT401 in plasma following single and multiple IV doses in healthy volunteers.

    PK parameters to be evaluated include area under the concentration-time curve from 0 to time of last quantifiable concentration (AUClast)

    Time frame: Single Dose Cohorts: multiple timepoints pre-dose to 24 hours post-dose Multiple Dose Cohorts: *First and Last Dose: multiple timepoints from pre-dose to 4 hours post-dose

  2. To measure the PK of PVT401 in plasma following single and multiple IV doses in healthy volunteers.

    PK parameters to be evaluated include area under the concentration-time curve from 0 to infinity (AUCinf)

    Time frame: Single Dose Cohorts: multiple timepoints pre-dose to 24 hours post-dose Multiple Dose Cohorts: *First and Last Dose: multiple timepoints from pre-dose to 4 hours post-dose

  3. To measure the PK of PVT401 in plasma following single and multiple IV doses in healthy volunteers.

    PK parameters to be evaluated include maximum concentrations (Cmax);

    Time frame: Single Dose Cohorts: multiple timepoints pre-dose to 24 hours post-dose Multiple Dose Cohorts: *First and Last Dose: multiple timepoints from pre-dose to 4 hours post-dose

  4. To measure the PK of PVT401 in plasma following single and multiple IV doses in healthy volunteers.

    PK parameters to be evaluated include time at which the maximum concentration is observed (tmax);

    Time frame: Single Dose Cohorts: multiple timepoints pre-dose to 24 hours post-dose Multiple Dose Cohorts: *First and Last Dose: multiple timepoints from pre-dose to 4 hours post-dose

  5. To measure the PK of PVT401 in plasma following single and multiple IV doses in healthy volunteers.

    PK parameters to be evaluated include apparent terminal elimination half-life (t1/2)

    Time frame: Single Dose Cohorts: multiple timepoints pre-dose to 24 hours post-dose Multiple Dose Cohorts: *First and Last Dose: multiple timepoints from pre-dose to 4 hours post-dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 19 months is above that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 20, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07423000
Lead sponsor
Parvus Therapeutics, Inc.
Collaborators
Southern Star Research
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Apr 13, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Sarah Executive Director, Clinical Operations
Contact
sgrimberg@parvustx.com
+1 949 378 0896

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion